Diabetes mellitus/poststroke hyperglycemia: a detrimental factor for tPA thrombolytic stroke therapy

Y Jiang, N Liu, J Han, Y Li, P Spencer… - Translational stroke …, 2021 - Springer
Intravenous administration of tissue-type plasminogen activator (IV tPA) therapy has long
been considered a mainstay in ischemic stroke management. However, patients respond to …
被引用次数：37 相关文章

Diabetes Mellitus/Poststroke Hyperglycemia: a Detrimental Factor for tPA Thrombolytic Stroke Therapy

Y Jiang, N Liu, J Han, Y Li, P Spencer… - Translational Stroke …, 2021 - search.proquest.com
Intravenous administration of tissue-type plasminogen activator (IV tPA) therapy has long
been considered a mainstay in ischemic stroke management. However, patients respond to …

Diabetes Mellitus/Poststroke Hyperglycemia: a Detrimental Factor for tPA Thrombolytic Stroke Therapy.

Y Jiang, N Liu, J Han, Y Li, P Spencer… - Translational Stroke …, 2020 - europepmc.org
Intravenous administration of tissue-type plasminogen activator (IV tPA) therapy has long
been considered a mainstay in ischemic stroke management. However, patients respond to …

Diabetes Mellitus/Poststroke Hyperglycemia: a Detrimental Factor for tPA Thrombolytic Stroke Therapy

Y Jiang, N Liu, J Han, Y Li… - Translational …, 2021 - pubmed.ncbi.nlm.nih.gov
Intravenous administration of tissue-type plasminogen activator (IV tPA) therapy has long
been considered a mainstay in ischemic stroke management. However, patients respond to …